Orexigen Therapeutics will cut several programs in order to focus on its obesity drugs, Contrave and Empatic. Proof-of-concept Phase II trials for OREX-003 (zonisamide and olanzapine to mitigate antipsychotic-associated weight gain) and OREX-004 (fluoxetine and naltrexone to reduce symptoms of obsessive-compulsive disorder) have been discontinued. The company will hold onto its intellectual property in these assets and retains the option to restart both programs. Orexigen is directing all of ...